DELEX Therapeutics Selected to Present at Springboard: New England 2003
MISSISSAUGA, Ontario, Nov. 20, 2003 /PRNewswire/ -- DELEX Therapeutics today announced that Dr. Diana Pliura, President and CEO, will present a review of the Company's proposed clinical program with respect to its lead product candidate, AeroLEF and outline its progress to date at Springboard: New England 2003, being held in Wellesley, Massachusetts on Nov. 21, 2003. Co- hosted by the Center for Women & Enterprise and Springboard Enterprises, the fourth annual Springboard: New England Forum will feature 16 of the strongest women entrepreneurs in the technology and life sciences sectors. These women were culled from an impressive applicant pool, ranging from seed to later stage financing rounds, to present their business opportunities to more than 200 leading venture capital, corporate and angel investors in the New England and New York regions.
"DELEX is pleased and excited to have the opportunity to participate in this high-profile venture capital forum," stated Dr. Diana Pliura. "By facilitating connections within the US financial community, we believe Springboard has accelerated the Company's access to international equity markets, potentially leading to new capital and business opportunities."
"Springboard: New England has created enormous opportunities for women entrepreneurs; last year's presenters raised $34 million to date in investments and pulled in numerous grants, contracts and awards. In total, the 75 companies presenting in New England since 2000 have raised more than $400 million," said Amy Millman, President, Springboard Enterprises. "One thing is true of all these women - they have been selected to present at Springboard because they have solid businesses that offer great investment opportunities. We're looking forward to helping them secure funding for technologies, products and services that will shape the future."
Earlier this month, DELEX received approval from the Therapeutics Product Directorate of Health Canada to initiate a Phase II clinical trial of AeroLEF(TM) (aerosolized liposome encapsulated fentanyl). The approved study will assess the safety and efficacy of AeroLEF(TM) in hospitalized knee surgery patients experiencing acute post-surgical pain.
About DELEX Therapeutics:
DELEX Therapeutics Inc. is a privately held, clinical-stage biopharmaceutical company that develops proprietary drugs for systemic delivery following inhalation via the lung. The Company is developing its proprietary technology platform, ROSE-DS(TM) (Rapid Onset and Sustained Effect Delivery System) to offer a unique combination of drug delivery attributes, including needle-free delivery by simple inhalation, a rapid onset of action comparable to intravenous administration, a sustained effect, and personalized, incremental dosing that allows for the adjustment of dosing to a patient's specific needs. In addition, DELEX believes its ROSE-DS(TM) technology platform will expand the range of therapeutic options for patient populations with unmet medical needs. The Company's lead product candidate, AeroLEF(TM), is being developed to provide next-generation pain relief for acute and cancer pain indications in the hospital and outpatient settings.
About Springboard Enterprises:
Springboard is a national non-profit organization dedicated to accelerating women's access to the equity markets. Since the first Springboard Forum in January 2000, thousands of investors, service providers, financiers, entrepreneurial institutions and business leaders have actively participated in recruiting, screening and coaching Springboard companies. Springboard patrons and venture affiliates include the Ewing Marion Kauffman Foundation, George Washington University, Grant Thornton, McKinsey & Co., Foley Hoag, NVCA and the Kauffman Fellows Program. For more information, visit . http://www.springboardenterprises.org/
About the Center for Women & Enterprise:
Founded in 1995, the Center for Women & Enterprise (CWE) is the largest regional entrepreneurial training organization in Boston and Worcester, Massachusetts and Providence, Rhode Island. CWE offers education, training, technical assistance, women's business enterprise certification and access to both debt and equity capital to entrepreneurs at every stage of business development. CWE draws clients from a wide variety of racial, ethnic and socio-economic backgrounds, spanning the range from women living in public housing who may want to start home-based or small retail businesses to women running fast growth, multi-million dollar technology businesses. As a non- profit, charitable organization, CWE provides its services on a sliding-scale basis in order to serve all women, regardless of their ability to pay. Since its founding in 1995, CWE has served nearly 4000 entrepreneurs.
CONTACT: Dr. Diana Pliura, President & CEO, DELEX Therapeutics Inc.,6535 Millcreek Dr., Unit 62, Mississauga, ON, L5N 2M2, Tel. (905) 812-0073;Fax (905) 812-0059, email@example.com
Terms and conditions of use apply
Copyright © 2003 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2003